YSG

Ladies and gentlemen, good day, and welcome to the Yatsen First Quarter 2026 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Irene Lyu, Vice President, Head of Strategic Investment and Capital Markets. Please go ahead.

Thank you, operator. Please note that discussion today will contain forward-looking statements relating to the company's future performance and are intended to qualify for the safe harbor from liability as established by the U.S. Private Securities Litigation Reform Act. Such statements are not guarantees of future performance and are subject to certain risks and uncertainties, assumptions, and other factors. Some of these risks are beyond the company's control and could cause actual results to differ materially from those mentioned in today's press release and this discussion. A general discussion of the risk factors that could affect Yatsen's business and financial results is included in certain filings of the company with the Securities and Exchange Commission. The company does not undertake any obligation to update this forward-looking information except as required by law. During today's call, management will also discuss certain non-GAAP financial measures for comparison purposes only.

Please see the earnings release issued earlier today for a definition of non-GAAP financial measures and a reconciliation of GAAP to non-GAAP financial results. Joining us today on the call from Yatsen senior management are Mr. Jinfeng Huang, our Founder, Chairman, and CEO, and Mr. Donghao Yang, our CFO and Director. Management will begin with prepared remarks. The call will conclude with a Q and A session. As a reminder, this conference is being recorded. A webcast replay of this conference call will be available on Yatsen's investor relations website at ir.yatsenglobal.com. I'll now turn the call over to Mr. Jinfeng Huang. Please go ahead, sir.

Thanks, Irene. Hi, everyone, and thank you for joining our first quarter 2026 earnings conference call. Going into this year, we delivered top-line growth that met our period guidance range and demonstrated ongoing resilience of our multi-brand strategy. Our financial and operational highlights this quarter further show that Yatsen is navigating the market with a clear strategic vision. Looking at the macro environment, according to the National Bureau of Statistics, beauty retail sales grew by 5.9% year-over-year in the first quarter of 2026, reflecting a stable yet highly competitive domestic beauty market. Looking closely at the online channels, the combined sales across Tmall and Douyin, and JD.com also recorded a single-digit year-over-year growth. Against this market backdrop, our strategic rebalancing has yielded highly encouraging results. Our total net revenues stayed on a steady growth trajectory, growing by 22.5% year-over-year for the first quarter.

More importantly, this growth was primarily propelled by the sustained upward momentum of our skincare brand, which experienced another substantial year-over-year growth of 68.5%. Driven by this favorable shift toward our skincare offering, our gross margin continued its year-over-year expansion and reached a historical milestone of 18.2%, reinforcing the structural health of our business model. Throughout the first quarter, we remained fiercely committed to our core strategic initiatives. Specifically, we continued to drive R&D-led product innovation, strengthen brand equity across our multi-brand portfolio, and position our business for long-term profitability optimization. In the following section, I would like to share our key progress across each of these three strategic pillars. Our first pillar is driving R&D-led innovation, which remains the ultimate engine behind our sustainable growth.

In the first quarter, we consistently stepped up our R&D investments, with R&D expenses as a percentage of total net revenues increasing further to 3.9%. This ongoing commitment allowed us to broaden our scientific initiatives. For instance, Dr. Wu launched the fourth Dr. Wu Acne Research Fund project in March, bringing online and offline dermatological experts to tackle a series of specialized research topics. In April, the brand marked another milestone with the release of the white paper on Chinese dermatological research and skin renewal. Leveraging 48 years of clinical expert trials and skin insights, this publication officially defines a multi-ingredient, multi-target, and a full-layer skin renewal management framework, further solidifying the brand's authority in dermatology. On the product front, our advanced R&D systems have successfully powered a series of highly market-ready solutions.

During the first quarter, Galénic's new Couture Révélation Cellulaire Revitalising Cream was an instant hit, selling out soon after its debut.

Dr. Wu expanded its successful PDRN series with the introduction of two new breakthrough products, the Ageversal Sodium DNA Hydro-Luminous Mask, and the Ageversal Advanced Rejuvenate Eye Cream. Meanwhile, this launch also expanded its product portfolio by launching the Renewal Intensive Treatment, designed specifically for the dedicated eye area. These launches underscore our enhanced efficiency in expanding existing series into new categories and broader equities. Our second pillar is strengthening brand equities through our portfolio through expert-led communication and strategic brand activities. In March, Galénic made a high profile appearance at the AMWC, the Aesthetic and Anti-Aging Medicine World Congress in Monaco. This world class presentation further reinforced Galénic's scientific credentials and solidified its core consumer mindshare in cellular level anti-aging skincare.

Furthermore, in April, Galénic announced the appointment of Fan Chengcheng as the new brand ambassador, a move that has amplified its brand resonance and consumer awareness. Our third pillar is improving overall profitability. During the third quarter, our selling and marketing expenses as a percentage of total net revenues experienced an increase as a result of both the continued investment in building our core brands and the elevated industry-wide traffic acquisition costs on the Douyin platform. Our commitment to long-term profitability optimization remains unwavering. Moving forward, we will dynamically adjust our channel mix, streamline our operational expenses, and unlock greater operational leverage from our fixed costs. These initiatives will ensure that our top-line expansion efficiently translates into further margin improvement, paving the way of sustainable profit-centric growth. Finally, I would like to provide an important update regarding our recent financing transaction.

Following our announcement on March 11th, we are pleased to note that we successfully completed the first tranche of the private placement of convertible notes and warrants on May 31st, 2026. In addition to myself and Cha Capital, we are delighted to welcome Hillhouse as a key participating investor in this offering. This successful closing serves as a powerful testament to our long-term investors' steadfast confidence in Yatsen's strategic direction and further value. Management shares this exact same confidence, and we are fully energized to deliver sustained value for our shareholders in the quarters to come. With that, I will now turn the call over to our CFO, Donghao Yang, to discuss our financial details.

Thank you, David, and hello everyone. Before I get started, I would like to clarify that all financial numbers presented today are unified amounts and all percentage changes refer to year-over-year changes unless otherwise noted. Total net revenues for the first quarter of 2026 increased by 22.5% to CNY 1.02 billion from CNY 833.5 million for the prior year period. The increase was primarily due to a 58.5% year-over-year increase in net revenues from skincare brands, partially offset by a 5% year-over-year decrease in net revenues from color cosmetics brands. Gross profit for the first quarter of 2026 increased by 24.3% to CNY 819.2 million from CNY 659.1 million for the prior year period. Gross margin for the first quarter of 2026 increased to 80.2%, from 79.1% for the prior year period.

Total operating expenses for the first quarter of 2026 increased by 32.5% to CNY 918.1 million from CNY 693.2 million for the prior year period. As a percentage of total net revenues, total operating expenses for the first quarter of 2026 were 89.9%, as compared with 83.2% for the prior year period. Fulfillment expenses for the first quarter of 2026 were CNY 61.1 million as compared with CNY 51.8 million for the prior year period. As a percentage of total net revenues, fulfillment expenses for the first quarter of 2026 decreased to 6%, from 6.2% for the prior year period. The decrease was primarily due to further improvements in logistics efficiency. Selling and marketing expenses for the first quarter of 2026 were CNY 737.2 million as compared with CNY 553.8 million for the prior year period.

As percentage of total net revenues, selling and marketing expenses for the first quarter of 2026 increased to 72.2%, from 66.4% for the prior year period. The increase was primarily driven by investments in broadening consumer awareness and building long-term brand equity of our core brands, coupled with higher traffic acquisition costs on the Douyin platform. General and administrative expenses for the first quarter of 2026 were CNY 80.3 million, as compared with CNY 64.9 million for the prior year period. As a percentage of total net revenues, general and administrative expenses for the first quarter of 2026 were 7.9%, as compared with 7.8% for the prior year period, remaining largely flat. Research and development expenses for the first quarter of 2026 were CNY 39.4 million, as compared with CNY 22.6 million for the prior year period.

As a percentage of total net revenues, research and development expenses for the first quarter of 2026 increased to 3.9%, from 2.7% for the prior year period. The increase was primarily driven by higher payroll expenses resulting from a rise in research and development headcount. Loss from operations for the first quarter of 2026 was CNY 99 million, as compared with CNY 34.1 million for the prior year period. Operating loss margin was 9.7%, as compared with 4.1% for the prior year period. Non-GAAP loss from operations for the first quarter of 2026 was CNY 84.6 million, as compared with CNY 14.9 million for the prior year period. Non-GAAP operating loss margin was 8.3%, as compared with 1.8% for the prior year period. Net loss for the first quarter of 2026 was CNY 61.9 million, as compared with CNY 5.6 million for the prior year period.

Net loss margin was 6.1%, as compared with 0.7% for the prior year period. Net loss attributable to Yatsen's ordinary shareholders per diluted ADS for the first quarter of 2026 was RMB 0.64, as compared with RMB 0.06 for the prior year period. Non-GAAP net loss for the first quarter of 2026 was RMB 57.3 million, as compared with non-GAAP net income of RMB 7.1 million for the prior year period. Non-GAAP net loss margin was 5.6%, as compared with non-GAAP net income margin of 0.9% for the prior year period. Non-GAAP net loss attributable to Yatsen's ordinary shareholders per diluted ADS for the first quarter of 2026 was RMB 0.6, as compared with non-GAAP net income attributable to Yatsen's ordinary shareholders per diluted ADS of RMB 0.07 for the prior year period.

As of March 31st, 2026, the company had cash, restricted cash, and short-term investments of CNY 934.2 million, as compared with CNY 1.05 billion as of December 31st, 2025. Net cash used in operating activities for the first quarter of 2026 was CNY 90 million, as compared with net cash generated from operating activities of CNY 23.8 million for the prior year period. Looking at our business outlook for the second quarter of 2026, we expect our total net revenues to be between CNY 1.2 billion and CNY 1.3 billion, representing a year-over-year increase of approximately 10%-20%. These forecasts reflect the company's current and preliminary views on the market and operational conditions, which are subject to change. With that, I would now like to open the call to Q and A. Operator?

Thank you. We will now begin the question-and-answer session. To ask a question, you may press star then one on your telephone keypad. To remove yourself from queue, please press star then two. For the benefit of all participants on today's call, if you wish to ask your question to management in Chinese, please immediately repeat your question in English. Our first question today comes from Manqi Huang with CICC. Please go ahead.

Well, thanks for taking my question. This is Manqi Huang from CICC. I have two questions. About my first question, we've seen a rapid growth of our skincare brands in this quarter. Could management share with us how to expand our product portfolio of skincare brands going forward? My second question is that how do we view the competition from foreign brands, especially in high-end skincare markets? That's my two questions. Thank you.

Thank you, Manqi. We'll continue to expand around proven hero product families. In quarter one, Galénic's new anti-aging cream was a great success and sold out shortly after launch. We also saw significant growth from Galénic's snow algae facial moisturizer cream. These results give us more confidence that Galénic can expand from hero serums into a broader anti-aging skincare routine. For Dr. Wu and Yuesao, we'll follow the same logic. Build complete routines around proven science, strong efficacy, and clear consumer demand. For the second question regarding the competition from high-end foreign brands, competition is very intense, but we believe we have a differentiated position. Our skincare brands combine global heritage, strong scientific credibility, local consumer insights, and very fast execution. Galénic is a very great example. We are building the brand around cellular-level anti-aging, supported by successful product launches and stronger brand communication.

We are also using AI and data tools to improve consumer insights, content production, CIM, and marketing ROI. This helps us to compete more efficiently, not just to sell more. Thank you.

Thank you. As a reminder, if you would like to ask a question, please press star then one on your telephone keypad. Our next question today comes from Lin Zhang at CITIC Securities. Please go ahead.

Thank you for taking my question. I'm Lin Zhang from CITIC Securities. My question is that we have noticed Dr. Wu is growing really fast. Could you please share with us the key drivers of the growth? Thank you.

Well, Dr. Wu is a very important case for us. The brand has delivered strong growth while maintaining a healthier profitability profile. One reason is its higher B2B channel mix, including professional and offline channels. Which give us the brand a better balance between growth, traffic cost, and profitability. This is a model we want to learn from and then selectively apply to other skincare brands. Stronger science, more professional credibility, more balanced channel mix, and better marketing efficiency. Those are some of the key drivers we summarized for Dr. Wu. Thank you.

Thank you. That concludes the question-and-answer session. I would like to turn the conference back over to management for any additional or closing comments.

Thank you once again for joining us today. If you have any further questions, please feel free to contact us at Yatsen directly. Our contact information for IR in both China and the U.S. can be found in today's press release. Thank you, and have a great day.

Thank you. That concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.

Ladies and gentlemen, good day, and welcome to the Yatsen Fourth Quarter and Full Year 2025 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Sophia Peng, Investor Relations Manager. Please go ahead.

Thank you, operator. Please note that the discussion today will contain forward-looking statements relating to the company's future performance and are intended to qualify for the safe harbor from liability as established by the U.S. Private Securities Litigation Reform Act. Such statements are not guarantees of future performance and are subject to certain risks and uncertainties, assumptions and other factors. Some of these risks are beyond the company's control and could cause actual results to differ materially from those mentioned in today's press release and this discussion. A general discussion of the risk factors that could affect Yatsen's business and financial results is included in certain filings of the company with the Securities and Exchange Commission. The company does not undertake any obligation to update this forward-looking information, except as required by law. During today's call, management will also discuss certain non-GAAP financial measures for comparison purposes only. Please see the earnings release issued earlier today for a definition of non-GAAP financial measures and a reconciliation of GAAP to non-GAAP financial results. Joining us today on the call from Yatsen's senior management are Mr. Jinfeng Huang, our Founder, Chairman and CEO; and Mr. Donghao Yang, our CFO and Director. Management will begin with prepared remarks, and the call will conclude with a Q&A session. As a reminder, this conference is being recorded. In addition, a webcast replay of this conference call will be available on Yatsen's Investor Relations website at ir.yatsenglobal.com. I will now turn the call over to Mr. Jinfeng Huang. David, please go ahead, sir.

Hello, everyone. Thank you for joining Yatsen's fourth quarter and full year 2025 earnings call. I will start with a macro overview and our key financial performance, followed by an overview of our operational highlights under our key strategy initiatives over the past year. China's beauty industry maintained an upward trajectory throughout 2025. According to the adjusted data from the National Bureau of Statistics, beauty retail sales grew by 8.2% in the fourth quarter, the highest quarterly growth rate of the year. For the full year 2025, beauty retail sales grew by 5.1%, rebounding from the decline in 2024. While the market demonstrated robust recovery, the landscape was also marked by intensified competition, particularly during major shopping festivals. Against this backdrop of growing yet highly competitive market, we successfully executed our strategy initiatives to capitalize on the industry's upward momentum. Our total net revenue grew by 20.1% year-over-year for the fourth quarter, performing in line with our previous guidance and significantly outpacing the industry average. More importantly, this growth was driven by our Skincare brands, which accounted for 61.1% of our total net revenues in the fourth quarter. Our profitability also marked an improvement, recording net income under both GAAP and the non-GAAP measures for the fourth quarter. For the full year 2025, we also achieved a solid recovery in both revenue and profitability. Total net revenue returned to a growth trajectory increasing by 26.7% year-over-year to RMB 4.3 billion. Both our Color Cosmetics and Skincare brands delivered year-over-year growth with Dr. Wu and Galenic, serving as the primary drivers of this robust performance. For the full year, Skincare brands contributed 53% of our total net revenues. On the bottom line, we narrowed our full year net loss margin to 2.2% from 20.9% in the prior year while delivering a non-GAAP net income margin of 0.2%. This non-GAAP profitability turnaround is the direct result of our enhanced gross margin, optimized operational efficiencies and positive operating leverage from our top line growth. Our robust performance demonstrated the long-term value of our strategy transformation. Throughout the year, we remained steadfast in our commitment to 3 core initiatives: driving R&D-led product innovation, strengthening brand equities across our multi-brand portfolio and improving our overall profitability. I would now like to dive in deeper into these key focus areas. First, we leveraged our established R&D infrastructure to fuel a pipeline of innovative products, driven by proprietary ingredients development, open collaboration and application of AI in areas such as molecular structure prediction, our system efficiently translates cutting-edge technology into market-ready solutions. Our high-growth brands have all benefited from this refined R&D ecosystem with Galenic as a prime example. In September, Galenic launched the VB serum, further strengthening the brand's ABC cellular level skin care framework. The product saw a rapid surge in sales, becoming one of Galenic's top sellers and winning the breakthrough repairing serum of the year at the 2025 Cosmo Beauty Awards. In December, Galenic introduced another flagship innovation, the Couture Revelation Cellulaire reviving cream. Utilizing the brand's active anchor penetration technology, it delivers our exclusive patent anti-aging ingredient, Lumiskin deep into the skin to achieve significant firming and lifting effects. With these launches, Galenic has established a comprehensive presence across key skin care categories, including serums, creams and masks. We believe that our expanded product portfolio could not only optimize our channel mix by providing more offerings across different platforms, but also increase customer lifetime value by encouraging broader regime adoption. Second, we continue to focus on deepening the value and the market positioning of our brands. With a portfolio that spans from mass to premium and from color cosmetics to skin care, we possess a unique comprehensive view of the beauty industry. This allowed us to precisely address the evolving needs of diverse consumer segments. For example, by leveraging Dr. Wu's decades of expertise in clinical skin renewing treatments and capturing the latest trends in medical aesthetics, the brand launched the PDRN serum. This product is designed to meet growing consumer demand for clinic-inspired results from the comfort of home. Driven by these deep consumer insights, Dr. Wu experienced robust growth over the past year and was recognized as the annual growth breakthrough brand from Douyin. This success has further solidified Dr. Wu's brand authority and awareness in the skin renewing segment, effectively translating market momentum into long-term brand equity. Third, we remain dedicated to enhancing our profitability and operational excellence. We see clear opportunities to further improve profitability across several dimensions. To begin with, we are optimizing our product mix by prioritizing products with higher gross margins. Channel-wise, we plan to maximize marketing efficiencies through data-driven customer relationship management and a more stringent return on investment discipline while we are allocating spend toward higher return platforms. Beyond our front-end operations, we are also optimizing operational workflows to drive cost optimization. Lastly, as our top line continues to grow, we expect to gain operational leverage across our fixed expenses. So collectively, these initiatives bolster our confidence in delivering steady margin expansion while sustaining our growth momentum. In summary, 2025 was a pivotal year. Our R&D breakthroughs, deep consumer insights and enhanced operational efficiency have returned us to growth and optimize our profitability. Moving forward, we will stay committed to long term driving brand equity through innovation and delivering a quality profit-centric growth. Thank you. I will now turn the call to Donghao.

Thank you, David, and hello, everyone. Before I get started, I would like to clarify that all financial numbers presented today are in renminbi amount and all percentage changes refer to year-over-year changes unless otherwise noted. The total net revenues for the fourth quarter of 2025 increased by 20.1% to RMB 1.38 billion from RMB 1.15 billion for the prior year period. The increase was primarily due to a 51.9% year-over-year increase in net revenues from Skincare brands partially offset by a 9.1% year-over-year decrease in net revenues from Color Cosmetics brands. Gross profit for the fourth quarter of 2025 increased by 20% to RMB 1.07 billion from RMB 893 million for the prior year period. Gross margin for the fourth quarter of 2025 was 77.7%, remaining largely flat as compared with 77.8% for the prior year period. Total operating expenses for the fourth quarter of 2025 decreased by 15.6% to RMB 1.08 billion from RMB 1.28 billion for the prior year period. As a percentage of total net revenues, total operating expenses for the fourth quarter of 2025 were 78.6% as compared with 111.8% for the prior year period. Fulfillment expenses for the fourth quarter of 2025 were RMB 77 million as compared with RMB 63.5 million for the prior year period. As a percentage of total net revenues, fulfillment expenses for the fourth quarter of 2025 were 5.6% as compared with 5.5% for the prior year period, remaining largely flat. Selling and marketing expenses for the fourth quarter of 2025 were RMB 893.8 million as compared with RMB 690.6 million for the prior year period. As a percentage of total net revenue, selling and marketing expenses for the fourth quarter of 2025 increased to 64.8% from 60.1% for the prior year period. The increase was primarily driven by higher traffic acquisition costs amid intensified competition during the Double 11 shopping festival. General and administrative expenses for the fourth quarter of 2025 were RMB 74.4 million as compared with RMB 100.1 million for the prior year period. As a percentage of total net revenues, general and administrative expenses for the fourth quarter of 2025 decreased to 5.4% from 8.7% in the prior year period. The decrease was primarily driven by lower payroll expenses and share-based compensation expenses, coupled with the leveraging effect of higher total net revenues in the fourth quarter of 2025. Research and development expenses for the fourth quarter of 2025 were RMB 38.8 million as compared with RMB 26.3 million for the prior year period. As a percentage of total net revenues, research and development expenses for the fourth quarter of 2025 increased to 2.8% from 2.3% for the prior year period. The increase was primarily driven by higher payroll expenses resulting from rise in research and development headcount. There was no impairment of goodwill for the fourth quarter of 2025 as compared with an impairment of goodwill of RMB 403.1 million for the prior year period. Based on our assessment, no impairment indicators were identified as of December 31, 2025. Loss from operations for the fourth quarter of 2025 was RMB 12.7 million as compared with RMB 390.7 million for the prior year period. Operating loss margin was 0.9% as compared with 34% for the prior year period. Non-GAAP income from operations for the fourth quarter of 2025 was RMB 11.8 million as compared with RMB 93.2 million for the prior year period. Non-GAAP operating income margin was 0.9% as compared with 8.1% for the prior year period. Net income for the fourth quarter of 2025 was RMB 3 million as compared with net loss of RMB 378.8 million for the prior year period. Net income margin was 0.2% as compared with net loss margin of 33% for the prior year period. Net income attributable to Yatsen's ordinary shareholders per diluted ADS for the fourth quarter of 2025 was RMB 0.08 as compared with net loss attributable to Yatsen's ordinary shareholders per diluted ADS of RMB 3.98 for the prior year period. Non-GAAP net income for the fourth quarter of 2025 was RMB 41.2 million as compared with RMB 107 million for the prior year period. Non-GAAP net income margin was 3% as compared with 9.3% for the prior year period. Non-GAAP net income attributable to Yatsen's ordinary shareholders per diluted ADS for the fourth quarter of 2025 was RMB 0.46 as compared with RMB 0.99 for the prior year period. Now I would like to briefly walk you through the highlights of our full year results. Total net revenues for the full year of 2025 increased by 26.7% of RMB 4.3 billion from RMB 3.39 billion for the prior year period, primarily attributable to a 63.5% year-over-year increase in net revenues from Skincare brands, combined with a 1.9% year-over-year increase in net revenues from Color Cosmetics brands. Gross profit for the full year of 2025 increased by 28.4% to RMB 3.36 billion from RMB 2.62 billion for the prior period. Gross margin for the full year of 2025 increased to 78.2% from 77.1% for the prior year period. The increase was primarily attributable to increasing sales of higher-gross margin products. Loss from operations for the full year of 2025 was RMB 185.8 million as compared with RMB 824.9 million for the prior year period. Operating loss margin decreased to 4.3% from 24.3% for the prior year period, primarily because there was no impairment of goodwill for the full year of 2025. Non-GAAP loss from operations for the full year of 2025 was RMB 84 million as compared with RMB 224.3 million for the prior year period. Non-GAAP operating loss margin decreased to 2% from 6.6% for the prior year period. Net loss for the full year of 2025 was RMB 92.4 million as compared with RMB 710.2 million for the prior year period. Net loss margin decreased to 2.2% from 20.9% for the prior year period. Net loss attributable to Yatsen's ordinary shareholders per diluted ADS with the full year -- for the full year of 2025 was RMB 0.87 as compared with RMB 6.99 for the prior year period. Non-GAAP net income for the full year of 2025 was RMB 8.4 million as compared with non-GAAP net loss of RMB 128.2 million for the prior year period. Non-GAAP net income margin was 0.2% as compared with non-GAAP net loss margin of 3.8% for the prior year period. Non-GAAP net income was attributable to Yatsen's ordinary shareholders per diluted ADS for the full year of 2025 was RMB 0.19 as compared with non-GAAP net loss attributable to Yatsen's ordinary shareholders per diluted ADS of RMB 1.26 for the prior year period. As of December 31, 2025, we had cash, restricted cash and short-term investments of RMB 1.05 billion as compared with RMB 1.36 billion as of December 31, 2024. Net cash used in operating activities for the fourth quarter of 2025 was RMB 69.4 million as compared with net cash generated from operating activities RMB 202.2 million for the prior year period. Net cash used in operating activities for the full year of 2025 was RMB 94.7 million as compared with RMB 243.7 million for the prior year period. Looking at our business outlook for the first quarter of 2026, we expect our total net revenues to be between RMB 958.6 million and RMB 1.08 billion, representing a year-over-year increase of approximately 15% to 30%. These forecasts reflect our current and preliminary views on the market and operational conditions, which are subject to change. With that, I would now like to open the call to Q&A.

[Operator Instructions] And today's first question comes from Maggie Huang with CICC.

This is Maggie Huang from CICC. Firstly, congratulations for achieving a non-GAAP net income turnaround for the whole year. And I have 2 questions. My first question is that how do we plan to improve our net profit margin in this year? And my second question is about our plan to expand our profit portfolio for Skincare brands in this year. That's my 2 questions.

Well, thank you very much for your question. Regarding your first question, I think this year, we're going to continue to grow our Skincare business much faster than our Color Cosmetics business. And with Skincare business, the gross margin, net margin are typically much higher than Color Cosmetics brands. So by doing that, we're going to be able to improve our margin profile. And secondly, our top line will continue to grow this year. And as a leveraging effect, we do believe that our net margin will improve accordingly. And your second question regarding the growth of our Skincare business. I think the most important thing that we're going to do to grow our Skincare business is R&D. In the last 5, 6 years, we've been investing aggressively in our R&D capabilities. And if you look at the past -- especially the past 1 or 2 years, the phenomenal top line growth of our Skincare business has largely been due to the contribution of our R&D team in terms of better products which meet our consumers' demand.

Ladies and gentlemen, that does conclude the question-and-answer session. I'd like to turn the conference back over to management for any additional or closing comments.

Thank you all once again for joining us today. If you have any further questions, please feel free to contact us at Yatsen directly. Our contact information for IR in both China and the U.S. can be found in today's press release. Have a great day, everyone.

Thank you. That does conclude our conference for today. We thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.